


L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1999:134367 CAPLUS Full-text
 DN 130:247044
 TI Phenoxypyridines and pharmaceutical compositions containing them
 IN Ota, Tomoki; Nakanishi, Misa; Aibe, Izumi; Taguchi, Minoru; Tomisawa, Kazuyuki
 PA Taisho Pharmaceutical Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 8 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	JP 11049752	A2	19990223	JP 1997-210838	19970805 <--
PRAI	JP 1997-210838		19970805		
OS	MARPAT 130:247044				
GI					



I

AB Phenoxypyridines I (X = NO₂, NHR₄; R₄ = H, lower alkyl, carbamoyl, thiocarbamoyl, lower alkoxy carbonyl; R₁ = H, NO₂, lower alkyl; R₂ = H, lower alkyl, lower alkoxy, halo, cyano, lower perfluoroalkyl) or their pharmacol. acceptable salts are useful for pharmaceutical compns. The compns. are useful for inhibition of Na⁺/Ca²⁺ exchange systems, treatment or prevention of ischemic heart, brain, or kidney diseases, or cell-protecting agents in thrombolytic therapy or surgery for blood vessel formation, coronary artery bypass, or organ transplantation. The Na⁺/Ca²⁺ exchange activity of canine myocardial membrane vesicles was decreased to 48% of controls in the presence of 1 μM 2-[4-(3-fluorobenzoyloxy)phenoxy]-5-nitropyridine.